Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2019 10:00 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019

IRVING, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical...
October 10, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators

IRVING, Texas, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development,...
August 28, 2019 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations

IRVING, Texas, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Manmeet S. Soni as Chief...
August 08, 2019 06:40 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs

IRVING, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter...
August 01, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Programs on August 8, 2019

IRVING, Texas, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and...
June 05, 2019 18:00 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

IRVING, Texas, June 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the United States Food and Drug...
June 04, 2019 19:00 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)

IRVING, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s...
May 30, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces First Patient Enrolled in Phase 3 FALCON Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

IRVING, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the...
May 09, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs

Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019 FALCON Pivotal Phase 3 Trial to Initiate in May 2019 Conference Call With Management Scheduled for...
May 02, 2019 16:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit

IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that Colin Meyer, M.D., Reata’s Chief Medical...